Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China.
Surgery. 2020 Feb;167(2):340-351. doi: 10.1016/j.surg.2019.10.009. Epub 2019 Nov 21.
Early intravenous administration of tranexamic acid has been shown to protect the intestinal barrier after a model of trauma-hemorrhagic shock in the rat, but the potential mechanism remains unclear. Our previous studies have demonstrated that neutrophil extracellular traps contribute to the intestinal barrier dysfunction during sepsis and other critical conditions. Meanwhile, there are high levels of neutrophil infiltration in the intestine during trauma-hemorrhagic shock. Here, we hypothesized that neutrophil extracellular trap formation played a vital role during trauma-hemorrhagic shock-induced intestinal injury and that tranexamic acid, a serine protease inhibitor, may inhibit neutrophil extracellular trap formation and protect intestinal barrier function in trauma-hemorrhagic shock.
A model of trauma-hemorrhagic shock in male rats was established. The rats were divided into 6 groups: (1) sham group; (2) trauma-hemorrhagic shock group; (3) trauma-hemorrhagic shock + DNase I group; (4) trauma-hemorrhagic shock + tranexamic acid group; (5) trauma-hemorrhagic shock + tranexamic acid (different time) group; and (6) trauma-hemorrhagic shock + tranexamic acid (different doses) group. The DNase I solution was injected intravenously to disrupt neutrophil extracellular traps immediately after the trauma-hemorrhagic shock model was completed. After 24 hours, the small intestine and blood were collected for analysis. Human neutrophils were harvested and incubated with phorbol-12-myristate-13-acetate or tranexamic acid, generation of reactive oxygen species, and key proteins expression were detected.
Trauma-hemorrhagic shock induced the formation of intestinal neutrophil extracellular traps and disrupted the intestinal tight junction proteins. Clearing of neutrophil extracellular traps by DNase I resulted in increased expression of tight junction proteins and alleviated the intestinal injury. Early intravenous tranexamic acid administration (1 hour after trauma-hemorrhagic shock) decreased neutrophil extracellular trap formation and prevented tight junction protein disruption compared to the non-tranexamic acid group; however, after delayed administration of tranexamic acid (6 hours), there were no changes in neutrophil extracellular trap formation and intestinal injuries compared to the non-tranexamic acid group. Furthermore, tranexamic acid inhibited neutrophil extracellular trap formation and protected the intestinal barrier in a dose-dependent manner and high-dose (20 mg/kg) treatment of tranexamic acid showed a better effect compared with the therapeutic dose (10 mg/kg). The results of thromboelastography demonstrated that the R and K values in the high-dose group decreased (R, 1.85 ± 0.14 vs 3.87 ± 0.16 minutes, P < .001; K, 0.95 ± 0.04 vs 1.48 ± 0.07 minutes, P < .001), accompanied by a decrease in LY30, indicating that treatment with a high dose of tranexamic acid may cause hypercoagulability and shutdown of fibrinolysis. In addition, less neutrophil extracellular trap formation was detected in neutrophils incubated with neutrophils via an reactive oxygen species-dependent pathway.
We first demonstrated a novel role of neutrophil extracellular traps in the pathophysiology of intestinal barrier dysfunction during trauma-hemorrhagic shock. Notably, early but not delayed intravenous administration of tranexamic acid effectively inhibits neutrophil extracellular trap formation and protects intestinal barrier function. Therefore, these results suggested a potential theoretic intervention for the protection of the intestinal barrier during trauma-hemorrhagic shock. In such a process, tranexamic acid appears to regulate neutrophil extracellular trap formation via the classic reactive oxygen species/mitogen-activated protein kinase pathway.
已有研究表明,创伤性休克后早期静脉给予氨甲环酸可保护大鼠肠屏障,但潜在机制尚不清楚。我们之前的研究表明,中性粒细胞胞外诱捕网在脓毒症和其他危急情况下导致肠屏障功能障碍中起重要作用。同时,在创伤性休克时肠道内有大量中性粒细胞浸润。在这里,我们假设中性粒细胞胞外诱捕网的形成在创伤性休克诱导的肠损伤中起关键作用,而氨甲环酸作为丝氨酸蛋白酶抑制剂,可能通过抑制中性粒细胞胞外诱捕网的形成来保护创伤性休克时的肠屏障功能。
建立雄性大鼠创伤性休克模型。大鼠分为 6 组:(1)假手术组;(2)创伤性休克组;(3)创伤性休克+DNase I 组;(4)创伤性休克+氨甲环酸组;(5)创伤性休克+氨甲环酸(不同时间)组;(6)创伤性休克+氨甲环酸(不同剂量)组。创伤性休克模型建立完成后,立即静脉注射 DNase I 溶液破坏中性粒细胞胞外诱捕网。24 小时后,采集小肠和血液进行分析。收获人中性粒细胞,并用佛波醇 12-肉豆蔻酸 13-乙酸酯或氨甲环酸孵育,检测活性氧的产生和关键蛋白的表达。
创伤性休克诱导肠中性粒细胞胞外诱捕网形成,并破坏肠紧密连接蛋白。DNase I 清除中性粒细胞胞外诱捕网导致紧密连接蛋白表达增加,减轻肠损伤。早期静脉给予氨甲环酸(创伤性休克后 1 小时)与非氨甲环酸组相比,减少了中性粒细胞胞外诱捕网的形成,防止了紧密连接蛋白的破坏;然而,延迟给予氨甲环酸(6 小时)后,与非氨甲环酸组相比,中性粒细胞胞外诱捕网的形成和肠损伤没有变化。此外,氨甲环酸呈剂量依赖性抑制中性粒细胞胞外诱捕网的形成并保护肠屏障,高剂量(20 mg/kg)治疗的氨甲环酸效果优于治疗剂量(10 mg/kg)。血栓弹力图结果表明,高剂量组的 R 和 K 值降低(R,1.85±0.14 比 3.87±0.16 分钟,P<0.001;K,0.95±0.04 比 1.48±0.07 分钟,P<0.001),同时 LY30 降低,表明高剂量氨甲环酸治疗可能导致高凝和纤溶关闭。此外,通过活性氧依赖性途径孵育的中性粒细胞中检测到的中性粒细胞胞外诱捕网形成减少。
我们首次证明了中性粒细胞胞外诱捕网在创伤性休克时肠屏障功能障碍的病理生理学中的新作用。值得注意的是,创伤性休克后早期而非延迟静脉给予氨甲环酸可有效抑制中性粒细胞胞外诱捕网的形成并保护肠屏障功能。因此,这些结果为创伤性休克时肠屏障的保护提供了一种潜在的理论干预措施。在此过程中,氨甲环酸似乎通过经典的活性氧/丝裂原活化蛋白激酶途径调节中性粒细胞胞外诱捕网的形成。